Cardiovascular Systems Prices Public Offering of Common Stock

Cardiovascular Systems, Inc. (CSI) (CSII), a medical device company focused on developing and commercializing innovative interventional treatment systems for vascular disease, today announced the pricing of an underwritten public offering of 2,608,696 shares of its common stock, at a price to the public of $30.00 per share. The net proceeds to CSI from the sale of the shares, after deducting underwriting discounts and commissions and estimated expenses, are expected to be approximately $73.4 million. All of the shares in the offering are to be sold by CSI. The offering is expected to close on or about November 26, 2013.

In connection with the offering, CSI has also granted the underwriters a 30-day option to purchase up to an additional 391,304 shares.

Published: 21 November 2013
Written by Editor
Nasdaq   Healthcare   Up on News   Financing   Interesting News  
Read more: Cardiovascular Systems Inc ( CSII )

Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables

Unilife to receive $40MM in upfront and milestone payments
15-year supply agreement to launch initial 20 generic injectable drugs in syringes from Unifill platform
Unilife to begin commercial supply in FY 2014, annual minimum unit volume to exceed 175MM

Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma") (HIK.L) for the use of Unifill® prefilled syringes with a range of generic injectable drugs.

Published: 20 November 2013
Written by Editor
Nasdaq   Healthcare   New Product or Order   Up on News   Interesting News  
Read more: Unilife Corporation ( UNIS )

Titan Medical Inc. Confirms No Material Changes to Operations

At the request of IIROC, Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(TITXF) wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. Titan is developing a Single Port Orifice Robotic Technology (SPORT™) Surgical System for minimally invasive surgery. Titan recently announced that it had started tissue testing which has been highly successful in assessing and measuring the functionality of the SPORT™ Surgical System. Tissue testing constitutes the first major milestone on Titan's pathway to commercialization which is expected in 2015.

Published: 19 November 2013
Written by Editor
TSX Venture   Healthcare  
Read more: Titan Medical Inc ( TMD )

FONAR Announces First Fiscal 2014 Quarter Earnings Results

FONAR Corporation (NASDAQ: FONR)

  • First Fiscal 2014 Quarter net revenues increase 77% over First Fiscal Quarter 2013 to $16.8 million
  • First Fiscal 2014 Quarter net income increases 104% over First Fiscal Quarter 2013 to $3.6 million
  • Diluted Net Income Available to Common Stockholders for the First Fiscal 2014 Quarter was $0.37, an increase of 68% over First Fiscal Quarter 2013
  • FONAR records fifteenth straight quarter of positive net income and income from operations
    Published: 15 November 2013
    Written by Editor
    Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  
    Read more: FONAR Corporation ( FONR )

Organovo Reports Q2 Fiscal 2014 Results, Provides Business Update

Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its second quarter results and provided highlights of its recent activities.

Keith Murphy, Chairman and Chief Executive Officer of Organovo, commented on the results, "The quarter was marked by excellent progress across financial, operational and business development areas. Our progress in the development of 3D liver tissues has been exceptional, including the demonstration of 40 days of viability and functionality, and we remain on-track for releasing our first commercial liver toxicity assay product in calendar 2014. Our new strategic agreements are expected to assist in growing our commercial opportunities long term.

Published: 14 November 2013
Written by Editor
AMEX   Healthcare   Financial Results   Up on News   Interesting News  
Read more: Organovo Holdings Inc ( ONVO )
  1. Tandem Diabetes Care Inc ( TNDM )
  2. BioTelemetry Inc ( BEAT )
  3. ZELTIQ(R) ( ZLTQ )
  4. NuVasive Inc ( NUVA )
  5. BSD Medical Corporation ( BSDM )
Copyright © 2025 Stock Junction. All Rights Reserved.